C5 (UK) will be holding its 10th Annual Forum on Pharma Patent Lifecycles on June 21-22, 2011 in London, England. The conference will provide practical and strategic guidance on patent lifecycle extensions, including:
• The scope of SPCs for combination products and the cases referred to the ECJ;
• Recent cases on SPCs in Europe -- The originator perspective;
• Developing strategies to successfully monitor and manage SPCs on patent portfolios;
• The German Patent and Trade Mark Office (DPMA) perspective on tackling pharma and biotech patents;
• Examining potential anti-competitive practices and recent patent settlement agreements;
• Maximizing exclusivity for new medicinal products in light of regulatory and case law developments;
• Extending and protecting patent lifecycles in the BRIC countries;
• Structuring successful applications for selection patents and analyzing the various approaches in Europe;
• Guidance from the European Commission on lifecycle extensions;
• Classifying biosimilars and follow-on biologics in Europe and the U.S.;
• Preparing for the expiration of transitional provisions on paediatric extensions;
• Successfully obtaining preliminary injunctions to block exploitation from generic drugs; and
• The impact of U.S. developments on pharma lifecycle extensions.
In particular, C5 faculty will offer presentations on the following topics:
• A plethora of references: Medeva and its sequels -- keynote address by Hon. Mr. Justice Arnold, Chancery Division of the High Court of Justice;
• Recent cases on SPCs in Europe -- The Originator Perspective;
• Adopting strategies to overcome challenges based on recent industry trends;
• The German Patent and Trade Mark Office (DPMA) perspective on tackling biotech patents -- Dr. Roman Maksymiw, Head of Division, German Patent and Trade Mark Office;
• Combating practical challenges for the grant of SPCs;
• Examining potential anti-competitive practices and recent patent settlement agreements;
• The impact of US developments on pharma lifecycle extensions;
• Structuring successful applications for selection patents and analysing the various approaches in Europe;
• Maximising exclusivity for new medicinal products in light of regulatory and case law developments;
• Guidance from the European Commission on lifecycle extensions -- keynote address by Lavinia Teodorescu, Antitrust: Pharma and Health Services, DG Competition European Commission;
• Developing strategies to successfully monitor and manage SPCs on patent portfolios;
• Extending and protecting patent lifecycles in the BRIC countries;
• Preparing for the expiration of transitional provisions on paediatric extensions;
• Successfully obtaining preliminary injunctions to block exploitation from generic drugs;
• Classifying biosimilars and follow-on biologics in Europe and the US; and
• Monitoring the approval and grant processes of third party SPC applications.
A pre-conference workshop, entitled "Constructing Patent Settlement Agreements and Devising Effective SPC Strategies" will be offered from 1:00 pm to 4:30 pm on June 20, 2011.
The agenda for the Pharma Patent Lifecycles conference can be found here. A complete brochure for this conference, including an agenda, list of speakers, detailed descriptions of conference sessions, and registration form can be downloaded here.
The registration fee is £2197 for the conference and workshop and £1599 for the conference alone. Those registering by May 20, 2011 will receive a £100 discount. Those interested in registering for the conference can do so here, by calling +44 20 7878 6888, by faxing a registration form to +44 20 7878 6885, or by e-mailing [email protected].
In order for the plaintiff to win a patent lawsuit, they must prove to the court that they were in fact the original inventor, and that the defendant infringed their patent. The defendant must then prove one of the following in order to win the case:
• The patent was not infringed
• The patent is unenforceable
• The patent was never valid
Posted by: Jared | May 11, 2011 at 12:40 PM